PF-Atlas › Clinical Trials › NCT01266135

Safety and Efficacy of QAX576 in Patients With Idiopathic Pulmonary Fibrosis

QAX576 · Phase 2

Registry ID
NCT01266135
Phase
Phase 2
Status
Terminated
Drug / intervention
QAX576
Sponsor
Novartis Pharmaceuticals
Start
2010-12
Enrollment
40
Locations
10

About this trial

This study is designed to evaluate the safety, tolerability, pharmacokinetics and efficacy of QAX576 in patients with idiopathic pulmonary fibrosis.

View NCT01266135 on ClinicalTrials.gov →

Explore related

All QAX576 trialsAll IPF trials

Related trials

QAX576 — NCT00532233QAX576 — NCT00581997
Medical disclaimer. This page summarizes public trial data for NCT01266135 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.